KRISTEN KOLLER: Open Payments
NPI 1508131699 · WASHINGTON, DC. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$434 in 12 payments from 9 companies in 2025. Trend: 2023 $216 · 2024 $830 · 2025 $434
Food & beverage: $434
| Company | Payments | Amount |
|---|---|---|
| Gilead Sciences, Inc. | 1 | $127 |
| Boston Scientific Corporation | 2 | $76 |
| Lilly USA, LLC | 2 | $57 |
| Ipsen Biopharmaceuticals, Inc | 2 | $49 |
| ABBVIE INC. | 1 | $30 |
| Novo Nordisk Inc | 1 | $26 |
| Janssen Biotech, Inc. | 1 | $25 |
| Janssen Scientific Affairs, LLC | 1 | $23 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | 1 | $22 |
Products named: Livdelzi, OverStitch Endoscopic Suturing System, OMVOH, IQIRVO, TREMFYA, SKYRIZI, Wegovy, XIFAXAN.
Industry payments across DC — which companies pay providers there.
